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Pentoxifylline (PTX), a methyl xanthine derivative, is a phosphodiesterase inhibitor with anti-inflammatory and
renoprotective effects in diabetic patients, among other properties. We studied PTX actions and mechanisms in
reducing blood biochemical parameters, in diabetic rats. For diabetes induction, alloxan was intravenously
administered to male Wistar rats. One group was left untreated and the other ones treated with PTX (25, 50 and
100 mg/kg), glibenclamide or metformin, as references. Forty-eight hours later and after 1-week to 3-month
treatments, blood was collected for determination of glycemia, triglycerides, cholesterol, transaminases, fructosamine
and glycated hemoglobin. Afterwards, the animals were euthanized and pancreas, liver and kidney processed for
histological analyses and immunohistochemistry assays for TNF-alpha, iNOS and COX-2. The results showed that PTX
decreased glycemia and also triglyceride levels, starting 1 week after treatments, as compared to the same group
before treatments. Glycemia values were brought towards normality, after 1-month treatment. PTX hypoglycemic
effects were potentiated by glibenclamide but not by metformin. It also decreased fructosamine and glycated
hemoglobin. Some histological and immunohistochemical alterations for TNF-alpha, iNOS and COX-2 in the diabetic
pancreas were also reversed by PTX. We conclude that PTX acts similarly to glibenclamide, and its hypoglycemic actions
are, partly, a consequence of ATP-sensitive K+ channels inhibition. In addition, by its anti-inflammatory and antioxidant
properties, PTX may be a therapeutic alternative for the treatment of diabetes and its complications.
Keywords: Pentoxifylline; Diabetes mellitus; Inflammation; Oxidative stress; CytokinesIntroduction
Diabetes mellitus is a serious worldwide health problem
associated with acute and chronic complications. In type 2
diabetes, either the body does not produce enough insulin
or the cells ignore the insulin necessary for the use of glu-
cose as an energy supply. Insulin takes the sugar from the
blood into the cells. Diabetes complications occur when
glucose builds up in the blood instead of going into the
cells. Diabetes mellitus has been proposed (Hooper &
Hooper 2009) to be a vicious cycle of metabolically in-
duced inflammation, impaired insulin responsiveness and
loss of homeostatic signaling.
In the past years, researches have established a clear re-
lationship between chronic low-grade inflammation,* Correspondence: gbviana@live.com
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in any medium, provided the original work is pobesity and insulin resistance. Adipocytes and macro-
phages secrete inflammatory cytokines that activate ki-
nases in insulin sensitive organs, impairing the insulin
receptor function and interfering with downstream signal-
ing. A consequence of impaired insulin action is the excess
of lipid deposition in the liver and adipocytes, elevating
lipid metabolites (Hooper & Hooper 2009).
It is now clear that obesity is associated with a state of
chronic low inflammation (Wellen & Hotamisligil 2005).
The first molecular link between inflammation and obesity,
TNF-alpha, was identified when this inflammatory cytokine
was discovered to be over-expressed in adipose tissues of
rodent models of obesity (Hotamisligil et al. 1993; Sethi &
Hotamisligil 1999). As is the case in mice, TNF-alpha is
overproduced in the adipose as well as muscle tissues of
obese humans (Hotamisligil et al. 1995; Kern et al. 1995;
Sazhizadeh et al. 1996).n Open Access article distributed under the terms of the Creative Commons
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roperly credited.
Garcia et al. SpringerPlus 2014, 3:283 Page 2 of 11
http://www.springerplus.com/content/3/1/283Pentoxifylline (PTX) is a methylxanthine phospho-
diesterase inhibitor with anti-inflammatory effects and
immune-regulatory properties (Shan et al. 2012). Early evi-
dence showed that pentoxifylline is able to suppress the
synthesis of TNF-alpha in vitro and in vivo, and to protect
animals against endotoxin shock (Zabel et al. 1993). There
is now substantial evidence linking TNF-alpha to insulin
resistance in humans, animals and in vitro systems. Reports
(Hotamisligil 1999) suggest that the deletion of TNF-alpha
leads to increased insulin sensitivity, i.e., decreased insulin
resistance. Furthermore, insulin resistance is an important
component of the metabolic syndrome associated with
obesity. Early-stage insulin-resistance and related mild glu-
cose intolerance may be compensated by increased insulin
secretion (Borst 2004).
The activation of innate immunity, with the subsequent
development of a low-grade inflammation, is recognized
as a critical factor in the pathogenesis of diabetes mellitus
and its complications, including nephropathy. In this
sense, there is now evidence for the relevant contribution
of pro-inflammatory cytokines, as TNF-alpha, to insulin
resistance (Navarro-González et al. 2009). PTX, due to its
anti-inflammatory and anti-TNF-alpha properties, may be
beneficial in the management of proteinuria/microalbumi-
nuria in diabetic patients (Rodriguez-Morán & Guerrero-
Romero 2008; McCormick et al. 2008). Besides possessing
anti-inflammatory properties, in part due to its capacity
for decreasing TNF-alpha, PTX also reduces lipid peroxi-
dation in diabetic patients (Radfar et al. 2005).
Thus, the objectives of the present study were to eva-
luate the effects of PTX in alloxan-induced diabetic rats
and its mechanisms of action. The focus was on mea-
surements of glycemia, triglyceride levels and other blood
biochemical parameters, as well as glycated hemoglobin
and fructosamine. Besides, histological and immuno-
histochemistry analyses for TNF-alpha, iNOS and COX-2
in pancreas, liver and kidney from untreated and PTX-
treated diabetic rats were also performed.
Material and methods
Drugs and reagents
Alloxan monohydrate was purchased from Sigma Chemical
Co. (St. Louis, MO, USA). Pentoxifylline, glibenclamide and
metformin were from EMS Laboratory (São Paulo, Brazil)
and dissolved in distilled water before use. Kits for blood
biochemistry were from Lab Test Diagnóstica SA (Minas
Gerais, Brazil). All other reagents were of analytical grade.
Animals
Male Wistar rats (180–250 g) from the Animal House
of the Faculty of Medicine Estácio of Juazeiro do Norte
(Brazil) were housed under standard conditions, with
proper commercial diet and water ad libitum. The study
was approved by the Ethical Committee for AnimalResearch of the Faculty of Medicine of the Federal Univer-
sity of Ceará (No. 01/2011). The experiments were per-
formed according to the Guide for the Care and Use of
Laboratory Animals (USA, 1985).
Experimental protocols
In the 1st protocol, rats were distributed into groups of
10 animals. After 48 h of the alloxan-induced diabetes,
blood was collected for measurements of glycemia, tri-
glycerides (TG), total cholesterol and liver transami-
nases. The animals presenting glycemia levels equal to or
higher than 250 mg/dL were submitted to the daily oral
administration of PTX (25, 50 or 100 mg/kg), glibencla-
mide (GLI, 5 mg/kg) or metformin (MET, 50 mg/kg), for
1 week. Normal and untreated diabetic groups received
distilled water and were added as negative and positive
controls, respectively. In combination experiments, dia-
betic groups treated with PTX5 +GLI2 or PTX5 +MET5
were also included. One hour after the last drug adminis-
tration, the animals were weighted and blood collected
again for new biochemical measurements. In the 2nd
protocol, the same procedure was used, except that the
diabetic groups were orally treated with PTX (50 mg/kg),
for 1, 2 or 3 months. Water was orally administered to
untreated diabetic controls, for the same period.
Determination of biochemical parameters in sera from
alloxan-induced diabetic rats
Blood from the retro-orbital plexus was collected and cen-
trifuged at 3,000 rpm, 10 min, and biochemical parameters
(glucose, TG, cholesterol, AST and ALT) were determined
by standard procedures, according to the manufacturers’
instructions (Labtest, Brazil).
Evaluation of PTX hypoglycemic activity on diazoxide-
induced hyperglycemia in rats
Groups of 6 to 10 animals were divided into: 1) non-
diabetic controls untreated or treated with PTX (50 and
100 mg/kg) or GLI (5 mg/kg) and 2) diabetic rats untreated
or treated with PTX (50 and 100 mg/kg) or GLI (5 mg/kg).
One hour after treatments and immediately before the
diazoxide injection (DZD, 250 mg/kg, i.p.), blood was col-
lected and again at 1, 2 and 3 h after DZD, for glucose
determinations.
Effects of PTX on glycated hemoglobin and fructosamine
in diabetic rats
The rats were divided into groups of 6–14 animals. After
48 h of alloxan administration, blood was collected for deter-
mination of biochemical parameters. Diabetic animals were
daily treated with PTX (5 or 50 mg/kg) or GLI (2 mg/kg)
and the association of PTX5 +GLI2, for 1 month (fructo-
samine) or 2 months (glycated hemoglobin). Untreated
diabetic rats (positive controls) were also included for
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1 h after the last administration.Histological analyses of untreated and PTX-treated
diabetic rats
After decapitation of 3 animals from each group, pancreas,
liver and kidney were excised from diabetic rats, untreated
or treated for 1 week with PTX (5 and 50 mg/kg), GLI
(2 mg/kg) or the association of PTX5 +GLI2. Then, tissue
slices were fixed in 10% buffered formalin. Normal tissues
were included for comparisons. Paraffin blocks were pre-
pared for routine microscopic slices processing (5 μ sec-





































































































































































Figure 1 Effects of pentoxifylline (PTX) treatments (100, 50 and 25 mg/kg,
Glibenclamide (GLI, 5 mg/kg, p.o.) was used as reference. The values are mea
treatment, and C and D after longer treatments (1 week to 3-months) with PTX (5
PTX25: *p < 0.0102; GLI5: **p < 0.0014. B (TG), PTX100: **p < 0.0013; PTX50: ***p < 0
1 week: ***q = 42.27; 2 weeks: ***q = 18.78; 1 month: ***q = 31.82; 2 months: ***q
2 weeks: ***q = 18.18;1 month: ***q = 14.75; 2 months: ***q = 12.44; 3 months: ***
as the post hoc test or paired Student t test. All comparisons were done after (AImmunohistochemistry assays for COX-2, iNOS and
TNF-alpha in untreated and PTX-treated diabetic rats
Paraffin sections from pancreas, liver and kidney of un-
treated (diabetic controls) and PTX-treated (5 and 50 mg/kg,
1 week) diabetic rats were deparaffinized, dehydrated and
immersed in 0.1 M citrate buffer (pH 6) under microwave
heating (18 min), for antigen recovery. After cooling
(20 min), the sections were washed in PBS, followed by
endogenous peroxidase blockade. Then, they were incu-
bated overnight (at 4°C) with anti-COX-2 p65, anti-iNOS
or anti-TNF-alpha primary antibodies diluted in PBS-BSA,
according to the manufacturers’ instructions. At the next
day, they were washed in PBS and incubated (30 min) with
the biotinylated rabbit secondary antibody. After anotherB







































































































































































p.o.) on glycemia and triglyceride (TG) levels in diabetic rats.
ns ± SEM from 6–18 animals per group. A and B, after 1 week
0 mg/kg). A (Glycemia), PTX100: ***p < 0.0002; PTX50: ***p < 0.0001;
.0003; PTX25: **p < 0.0082; GLI5: ***p < 0.0004. C (Glycemia) - PTX50,
= 26.31’; 3 months: ***q = 29.63. D (TG) - PTX50, 1 week: ***q = 13.42;
q = 20.23. Data analyzed by One-way ANOVA, followed by Newman-Keuls





























































































































































































Figure 2 (See legend on next page.)
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Figure 2 Effects of a low dose (5 mg/kg, p.o.) of pentoxifylline (PTX), alone or combined to glibenclamide (GLI, 2 mg/kg, p.o.) or
metformin (MET, 5 mg/kg, p.o.), on glycemia (A) and TG (B) levels, after 1-week treatment of diabetic rats. The values are means ± SEM
from 5–15 animals per group. PTX5A vs. PTX5B: *p < 0.0443; PTX5A + GLI2A vs. PTX5A: *p < 0.0322; MET5A vs. MET5B: **p < 0.0026. Data analyzed
by the paired Student t test. All comparisons were done after (A) vs. before (B) treatments, in each group.
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conjugated streptavidin-peroxidase complex (ABC Vectas-
tain® complex, USA) and. after a final washing, stained
with DAB, counter-stained with Mayer hematoxylin, dehy-
drated and mounted for analyses.
Statistical analyses
The paired Student’s t test was used in analyses of bio-
chemical parameters, for comparing means of each diabetic
group before and after the PTX treatment. In other experi-
ments, One-way ANOVA and the Newman-Keuls as the
post hoc test were used for comparing results among treat-
ments. The data were considered statistically significant at
p < 0.05.
Results
Effects of PTX on blood biochemical parameters after
1-week and longer treatments
The 1-week treatment of diabetic rats with PTX (25, 50
and 100 mg/kg) decreased from 26 to 63% blood glu-
cose, as related to the same group before treatments.
While the treatment of diabetic rats with GLI5 brought
glycemia to normal levels, hyperglycemia was main-
tained in untreated diabetic controls [Figure 1A: F (9,
92) = 24.25, p < 0.0001]. A similar profile was observed
in triglyceride levels [Figure 1B: F (9, 86) = 15.20, p <
0.0001]. Total cholesterol and liver transaminases were
unaltered. Furthermore, PTX (50 mg/kg) decreased
from 60 to 76% glucose levels (mg/dL), after 1-week and
longer treatments, as compared to each group before
treatments or to untreated diabetic rats, respectively
[Figure 1C: F (9, 85) = 291.8, p < 0.0001]. Similarly, trigly-
ceride levels decreased by 50%, along treatments, as re-
lated to the same group before treatments [Figure 1D: F
(9, 73) = 73.88, p < 0.0001]. Cholesterol and liver transami-
nases remained unaltered (data not shown).
PTX hypoglycemic effects were potentiated by
glibenclamide but not by metformin
In order to study the mechanisms of PTX hypoglycemic
and hypotriglyceridemic actions, glucose and TG levels
were measured in diabetic animals treated with lower doses
of PTX (5 mg/kg) or GLI (2 mg/kg) or MET (5 mg/kg),
alone or associated, after 1-week treatments. We showed
that, while PTX decreased glycemia by 24%, its association
with GLI decreased these values by 57%, as related to the
same group before treatments or to untreated diabetic
groups. Besides, at the 3rd month of treatment, bloodglucose levels in this association group were completely
normalized (data not shown). On the other hand, in the
association of PTX with MET there was no significant
decrease in glycemia levels, and MET even blocked the
hypoglycemic effect of PTX [Figure 2A: F (11, 90) =
3.603, p < 0.0003]. A similar profile was observed for
TG [Figure 2B: F (11, 75) = 4.531, p < 0.0001].
PTX effects on diazoxide-induced hyperglycemia in
non-diabetic and diabetic rats
The results in diabetic rats untreated or treated with PTX
or GLI and administered with DZD showed a similar pro-
file among groups, with increases in glycemia values ran-
ging from 1.3 to 1.6 fold, as related to the zero time for
each group [Figure 3A: F (8, 45) = 11.12, p < 0.0001]. How-
ever, significant and time-dependent increases of 1.9, 2.2
and 2.3 folds were observed for glycemia values in non-
diabetic rats untreated or treated with PTX (50 mg/kg),
after 1, 2 and 3 h of DZD administration, respectively. On
the other hand, no changes were demonstrated for non-
diabetic rats treated with GLI (5 mg/kg), after DZD, in the
same observation period (Figure 3B).
PTX decreases fructosamine and glycated hemoglobin in
diabetic rats
PTX (50 mg/kg) decreased by 42% the fructosamine
values in diabetic rats, after 1-month treatment, as related
to untreated diabetic rats. At lower doses, PTX (2 mg/kg)
or GLI (2 mg/kg) decreased by only 13 and 26% fructosa-
mine values, respectively, while the association of these
two drugs caused a 55% decrease, as related to untreated
diabetic rats [Figure 4A: F (5, 34) = 8.136, p < 0.0001]. Sig-
nificant decreases of 62 and 46% were also observed in
glycated hemoglobin, 2 months after the alloxan-induced
diabetes, in rats treated with PTX (50 or 5 mg/kg), respect-
ively, as related to the untreated diabetic group. While
GLI2 alone decreased by 45% glycated hemoglobin, this
value decreased by 80%, after the association of PTX5 with
GLI2, indicating a potentiation of the effect [Figure 4B: F
(4, 41) = 20.45, p < 0.0001].
PTX reduced histological alterations in pancreas, liver and
kidney from diabetic rats
Figure 5 shows representative photomicrographs of histo-
logical analyses of pancreas, liver and kidney from un-
treated and PTX5 and 50- or GLI2-treated diabetic rats,
as well diabetic rats treated with the association of PTX5
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Figure 3 (See legend on next page.)
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Figure 3 Effects of pentoxifylline (PTX) on DZD-induced hypoglycemia, in diabetic (A) and non-diabetic (B) rats. The values are means ±
SEM from 6 animals per group. The animals were administered with DZD (250 mg/kg, i.p.). Blood was collected immediately after DZD
administration (0 h) and at 1 and 2 h later. DC = untreated diabetic control; DZD = diazoxide. A - DC vs. PTX50 + DZD, 0 h: **q = 5.778; 1 h:
*q = 4.943; 2 h: **q = 5.130; DC vs. GLI5 + DZD, 0 h: **q = 5.568; 1 h: *q = 4.267; 2 h: **q = 5.941 (One-way ANOVA, followed by Newman-Keuls as
the post-hoc test). B - **p < 0.05 vs. the same group, at 1 and 2 h after DZD administration (paired Student t test).
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uolated cells, pyknotic nuclei, presence of mononuclear in-
flammatory cells and dilated and ectasic blood vessels;
PTX50-treated: almost complete restoration of Langerhans
islets; PTX5-treated: moderate damage with vacuolated
cells and dilated and ectasic blood vessels; GLI2-treated: al-
most complete restoration of Langerhans islets; PTX5 +
GLI2-treated: diminished damage as related to PTX5-
treated rats, suggesting a synergic effect (Figure 5, upper
panel). Liver - untreated diabetic rats: hepatocyte cords with
dilation of the centerlobular vein; PTX50-treated: hepato-
cytes with cellular tumefaction and the presence of inflam-
matory foci (Figure 5, middle panel). Kidney - untreated
diabetic rats: presence of tubular epithelium vacuolization
and mononuclear inflammatory cells in the inter-tubular
space; PTX50-treated: hypocellularity of glomeruli with
discrete tumefaction of the tubular epithelium (Figure 5,
lower panel).
Immunohistochemical assays for COX-2, iNOS and TNF-alpha
Figure 6 shows representative immunohistochemistry
photomicrographs for COX-2, iNOS and TNF-alpha, in
pancreas, liver and kidney from untreated (diabetic con-
trols) and PTX-treated (5 and 50 mg/kg, 1 week) diabetic
rats. One can observe that, in the three assays, tissues
from untreated diabetic rats present a higher immunore-
activity (shown by arrows), as related to those of PTX-
treated diabetic rats.
Discussion
In the present work, we demonstrated that PTX signifi-
cantly reduces glycemia and triglyceride levels in alloxan-
induced diabetic rats, after its daily administration for
1 week. Prolonged treatments bring blood glucose concen-
trations to normality, while triglycerides decreased by 50%.
Our study showed a potentiation of the hypoglycemic ef-
fect of PTX by glibenclamide (GLI), after the two drugs
association at lower doses. GLI works by inhibiting the
ATP-sensitive potassium channels (KATP), in pancreatic beta-
cells. This inhibition causes cell membrane depolarization
and opening of the voltage-dependent calcium channel,
which results in increased intracellular calcium concentration
in the beta-cell and subsequent stimulation of insulin release
(Luzi & Pozza 1997). PTX, at least in part, shares with GLI
this mechanism of action.
Diazoxide (DZD) is used to inhibit inappropriate insu-
lin secretion, causing hypoglycemia (Marks & Samols1968). Its major mode of action is the opening of KATP
channels in the beta-cell membrane, with repolarization,
closure of voltage-dependent Ca2+ channels, and lowering
of [Ca2+] ic (Henquin & Meissner 1982; Trube et al. 1986;
Gilon & Henquin 1992). However, DZD has been pro-
posed to decrease the efficacy of Ca2+ on exocytosis (Flatt
et al. 1994; Renström & Rorsman 1996). In order to inves-
tigate whether PTX would block DZD hyperglycemia, as
GLI does, the effects of both drugs were studied on dia-
betic and non-diabetic rats administered with DZD.
Our results show that, in diabetic animals, PTX and
GLI presented a similar profile and did not prevent
DZD-induced increases in glucose levels. However, in
non-diabetic animals, while GLI blocked the increase in
glycemia levels after DZD, this effect was not observed after
PTX, when the animals treated with PTX+DZD behaved
similarly to those treated with DZD only. Such results sug-
gest that other factors, besides the KATP-dependent chan-
nels blockade, interfere with the PTX action.
The administration of PTX, for 1 and 2 months, to dia-
betic rats significantly decreased fructosamine and HbA1c
levels, as related to untreated diabetic controls. Both fructo-
samine and glycated hemoglobin are associated with micro-
vascular conditions in diabetic patients, and increased risk
for mortality and morbidity in hemodialysis patients (Selvin
et al. 2011; Shafi et al. 2013).
Our histological studies showed that changes in diabetic
pancreas were partly reversed after PTX treatment. Inter-
estingly, the diabetic group treated with the association of
lower doses of PTX and GLI showed a pancreas with di-
minished damage, as related to that of diabetic rats treated
with PTX alone. Similar results were also observed in dia-
betic liver and kidney. Previously (MartonJ et al. 1998), a
beneficial effect of PTX treatment was demonstrated in
rats submitted to acute pancreatitis and showed that PTX
very effectively decreased TNF-alpha and IL-6 production
under this condition.
Evidences (Coelho et al. 2012) indicate that the ad-
ministration of PTX, after the onset of acute pancrea-
titis, decreased levels of pro-inflammatory cytokines.
Other studies have shown that PTX exerts a protective
effect in animal models of diabetes (Stosic-Grujicic
et al. 2001a; Stosic-Grujicic et al. 2001b). These au-
thors showed that the administration of PTX to dia-
betic animals reduced the production of inflammatory
mediators and prevented the development of hypergly-






















































































































































Figure 4 Effects of pentoxifylline (PTX) on fructosamine levels
(A) and glycated hemoglobin (B) in diabetic rats, after 1- or
2-month treatments. The values are means ± SEM from 6 to 14
animals per group. A - DC vs. GLI5: ***q = 6.493; vs. PTX50: ***q = 6.374;
vs. PTX5: *q = 3.984; vs. GLI2: *q = 3.827; vs. PTX5 + GLI2: ***q = 8.148; vs.
GLI5: ***q = 6.493; PTX5 + GLI2 vs. PTX5: *q = 4.013. B - DC vs. PTX50:
***q = 9.118; vs. PTX5: ***q = 7.677; vs. GLI2: ***q = 7.062; vs. PTX5 +
GLI2: ***q = 12.32; PTX5 + GLI2 vs. GLI2: ***q = 6.265; vs. PTX5: ***q =
6.505 (One-way ANOVA, followed by Newman-Keuls as the post
hoc test). DC = untreated diabetic controls; GLI = glibenclamide.
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cytokine-mediated nitric oxide (NO) synthase pathway.
Furthermore, inducible nitric oxide synthase (iNOS) was
shown to play a role in fasting hyperglycemia, contributing
to hepatic insulin resistance, in a model of obese diabetic
mice (Fujimoto et al. 2005). These findings are very similar
to ours, except that we used another model and lower
PTX doses. Despite these differences, we demonstrated
that PTX decreased not only hyperglycemia but also TG
levels, in alloxan-induced diabetic rats.
In the present work, we demonstrated that the number
of iNOS immune-stained cells was lower in pancreas of dia-
betic rats, after the PTX treatment. It is largely accepted
that the induction of iNOS in pancreatic islets leads to in-
creased NO production associated with dysfunctional beta-
cells. Furthermore, a recent study (Muhammed et al. 2012)
with diabetic islets culture, exposed to phosphodiesterase
(PDE) inhibitors, showed a marked suppression of iNOS
mRNA, reduced nitrite production and increased insulin
secretion. Considering inflammatory cytokines and NO as
potential mediators of pancreatic beta-cell destruction in
diabetes, and since PTX is also a PDE inhibitor, these data
point out to the same direction as ours and emphasize the
potential benefit of PTX in this pathologic condition.
We also demonstrated that PTX treatment decreases
the number of cyclooxygenase (COX-2) immunopositive
cells in diabetic pancreas. COX-2 has been previously re-
ported (Persaud et al. 2004) to be the dominant isoform
and insulin-secretor in beta-cells under basal conditions.
The observation that hyperglycemia increases the produc-
tion of IL-1beta in human beta-cells and induces COX-2
expression, led these authors to suggest this to be a route
by which hyperglycemia contributes to beta-cell dysfunc-
tion. Another work (Ling et al. 2005) demonstrated that
the exposure of pancreatic beta-cells to IL-1beta induces
the expression of iNOS and COX-2, and the subsequent
formation of NO and prostaglandin E2 (PGE2) may impair
beta-cell function. Therefore, the authors concluded that
NO-affected COX-2 activity is directly linked to COX-2
gene transcription and protein expression in pancreatic
beta-cells, providing a new therapeutic strategy for the
management of diabetes mellitus.
In addition, PTX also decreases TNF-alpha immunore-
activity in diabetic pancreas, liver and kidney. Increased
Figure 5 Representative photomicrographs from HE staining of rat pancreas (upper panel), liver (middle panel) and kidney (lower panel) in
normal, untreated diabetic and diabetic rats treated with PTX (5 or 50 mg/kg, p.o.), GLI (2 mg/kg) or the association of PTX5 +GLI2, for
1 week (400X magnification).
Figure 6 Representative photomicrographs from immunohistochemistry assays for iNOS, COX-2 and TNF-alpha in pancreas (upper panel),
liver (middle panel) and kidney (lower panel) in normal, untreated diabetic (arrows showing immunopositive cells) and PTX-treated (5 and
50 mg/kg) diabetic animals, after 1 week (400X magnification).
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derived from obese rodents or humans, and has been im-
plicated as a causative factor in obesity-associated insulin
resistance and diabetes mellitus pathogenesis. Further-
more, current evidence suggests that the administration of
exogenous TNF-alpha to animals can induce insulin resist-
ance, whereas its neutralization can improve insulin sensi-
tivity (Moller 2000). Since plasma TNF-alpha is associated
to insulin resistance, one can assume that this cytokine
plays a significant role in the pathogenesis of chronic insu-
lin resistance in humans (Plomgaard et al. 2007). In
addition, PTX (50 mg/kg) administered to rats for 8 weeks
was shown to inhibit insulin resistance and prevent TNF-
alpha elevation, leukocyte infiltration and endothelial
pyknosis (El-Bassossy et al. 2011).
A recent work (Francés et al. 2013) studied the contribu-
tion of TNF-alpha intracellular pathway and oxidative stress
for the development of apoptosis, in the liver of diabetic
rats. Interestingly, iNOS inhibition significantly reduced
TNF-alpha levels. These data indicate that the regulation of
TNF-alpha and oxidative stress in the diabetic state could
be of therapeutic relevance for the improvement of compli-
cations linked to chronic hyperglycemia. Furthermore, re-
sults from most animal studies and randomized controlled
trials on diabetic kidney disease consistently demonstrated
that short-term use of PTX produces a significant reduction
of proteinuria and microalbuminuria (Badri et al. 2011).
In conclusion, we showed that pentoxifylline decreases
blood glucose and TG levels in diabetic rats. The pentoxi-
fylline hypoglycemic effects are similar to those of gliben-
clamide and, at least partly, related to the inhibition of
ATP-sensitive K+ channels. It also improves histological
changes and decreases the immunoreactivity to iNOS,
COX-2 and TNF-alpha, in diabetic pancreas, liver and
kidney. Thus, pentoxifylline by its anti-inflammatory
and antioxidant properties is a potential and alternative
drug for the treatment of diabetes mellitus and its
related complications.Competing interests
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